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Summary
Background Few data are available to support the choice between the two currently available pneumococcal conjugate 
vaccines (PCVs), ten-valent PCV (PCV10) and 13-valent PCV (PCV13). Here we report a head-to-head comparison of 
the immunogenicity and reactogenicity of PCV10 and PCV13.
Methods In this parallel, open-label, randomised controlled trial, healthy infants from two districts in Ho Chi Minh 
City, Vietnam, were randomly allocated (in a 3:3:5:4:5:4 ratio), with use of a computer-generated list, to one of 
six infant PCV schedules: PCV10 in a 3 + 1 (group A), 3 + 0 (group B), 2 + 1 (group C), or two-dose schedule (group D); 
PCV13 in a 2 + 1 schedule (group E); or no infant PCV (control; group F). Blood samples were collected from infants 
between 2 months and 18 months of age at various timepoints before and after PCV doses and analysed (in a blinded 
manner) by ELISA and opsonophagocytic assay. The trial had two independent aims: to compare vaccination 
responses between PCV10 and PCV13, and to evaluate different schedules of PCV10. In this Article, we present 
results pertaining to the first aim. The primary outcome was the proportion of infants with an IgG concentration of 
at least 0·35 µg/mL for the ten serotypes common to the two vaccines at age 5 months, 4 weeks after the two-dose 
primary vaccination series (group C vs group E, per protocol population). An overall difference among the schedules 
was defined as at least seven of ten serotypes differing in the same direction at the 10% level. We also assessed 
whether the two-dose primary series of PCV13 (group E) was non-inferior at the 10% level to a three-dose primary 
series of PCV10 (groups A and B). This trial is registered with ClinicalTrials.gov, number NCT01953510.
Findings Of 1424 infants screened between Sept 30, 2013, and Jan 9, 2015, 1201 were allocated to the six groups: 152 (13%) 
to group A, 149 (12%) to group B, 250 (21%) to group C, 202 (17%) to group D, 251 (21%) to group E, and 197 (16%) to 
group F. 237 (95%) participants in group C (PCV10) and 232 (92%) in group E (PCV13) completed the primary 
vaccination series and had blood draws within the specified window at age 5 months, at which time the proportion of 
infants with IgG concentrations of at least 0·35 µg/mL did not differ between groups at the 10% level for any serotype 
(PCV10–PCV13 risk difference –2·1% [95% CI –4·8 to –0·1] for serotype 1; –1·3% [–3·7 to 0·6] for serotype 4; –3·4% 
[–6·8 to –0·4] for serotype 5; 15·6 [7·2 to 23·7] for serotype 6B; –1·3% [–3·7 to 0·6] for serotype 7F; –1·6% [–5·1 to 1·7] 
for serotype 9V; 0·0% [–2·7 to 2·9] for serotype 14; –2·1% [–5·3 to 0·9] for serotype 18C; 0·0% [–2·2 to 2·3] for serotype 
19F; and –11·6% [–18·2 to –4·9] for serotype 23F). At the same timepoint, two doses of PCV13 were non-inferior to 
three doses of PCV10 for nine of the ten shared serotypes (excluding 6B). Reactogenicity and serious adverse events 
were monitored according to good clinical practice guidelines, and the profiles were similar in the two groups. 
Interpretation PCV10 and PCV13 are similarly highly immunogenic when used in 2 + 1 schedule. The choice of 
vaccine might be influenced by factors such as the comparative magnitude of the antibody responses, price, and the 
relative importance of different serotypes in different settings.
Funding National Health and Medical Research Council of Australia, and Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Streptococcus pneumoniae (pneumococcus) is a leading 
vaccine-preventable cause of serious infection in young 
children, and was estimated to cause 294 000 deaths among 
children younger than 5 years of age in 2015.1 The greatest 
burden of pneumococcal disease and related mortality is in 
low-income and middle-income countries (LMICs).
Two pneumococcal conjugate vaccines (PCVs) are 
currently licensed for infant vaccination against 
pneumo coccus. 13-valent PCV (PCV13) contains 
pneumo coccal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F, and 23F. Ten-valent PCV (PCV10) 
contains ten of these serotypes (except serotypes 3, 6A, 
and 19A), although there is evidence for some cross-
protection against serotype 6A and 19A disease.2–4 PCV10 
and PCV13 have been shown to be immunologically 
non-inferior to the first-licensed, seven-valent PCV 
(PCV7),5–7 but there are few data directly comparing 
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PCV10 with PCV13, despite these vaccines having been 
available for several years. A trial from Papua New 
Guinea compared three doses of PCV10 and PCV13 
administered at 1 month, 2 months, and 3 months of 
age, with immunogenicity data obtained prevaccination, 
after dose three, and at 9 months of age.8 Two European 
trials of investigational next-generation pneumococcal 
vaccines have included control groups of both PCV10 
and PCV13, administered in a 3 + 1 schedule at 2 months, 
3 months, 4 months, and 12–15 months of age, with 
immunogenicity data obtained post-primary series, pre-
booster, and post-booster.9,10 Two other trials with post-
primary series immunogenicity data available are 
registered on ClinicalTrials.gov: a trial from The Gambia 
of investi gational, protein-based pneumococcal vaccines 
administered in a 3 + 0 schedule that includes both 
PCV10 and PCV13 control groups (NCT01262872); and a 
trial from Mexico to evaluate mixed regimens that 
includes groups that received a two-dose primary series 
of either PCV10 or PCV13 (NCT01641133). In addition, a 
small, non-randomised study from the Netherlands 
compared booster responses to PCV10 and PCV13 given 
in a 3 + 1 schedule.11 Broadly, these studies have shown 
that both PCV10 and PCV13 are highly immunogenic 
post-primary series and post-booster. Serotype-specific 
geometric mean concentrations (GMCs) of IgG anti-
body after vaccination with PCV13 tend to be higher 
post-primary series, lower pre-booster, and higher 
post-booster than GMCs after PCV10 vaccination, 
although these trends do not hold for all serotypes. 
Notably, of these studies, only the Papua New Guinean 
study8 and the Dutch study11 of the booster response 
were designed specifically to evaluate differences in the 
immuno genicity of the two vaccines.
Given the few comparative data, particularly data from 
LMICs, available to influence the choice of PCV, we did a 
randomised controlled trial in Vietnam (the Vietnam 
Pneumococcal Project) of different infant pneumococcal 
vaccination schedules, including a head-to-head com-
parison of PCV10 and PCV13 delivered in a 2 + 1 schedule , 
one of the schedules recommended by WHO.12 The trial 
had two independent aims: to compare vaccination 
responses between PCV10 and PCV13, and to evaluate 
different schedules of PCV10. In this Article we present 
results pertaining to the first aim.
Methods
Study design and participants
We designed a parallel, open-label, randomised con-
trolled trial to investigate simplified childhood 
vaccination schedules that are appropriate for use in 
LMICs. The trial was conducted in two districts within 
Ho Chi Minh City, Vietnam. Infants with no significant 
maternal or perinatal history and who were born at or 
after 36 weeks’ gestation were enrolled at 2 months of 
age and followed up to 24 months of age. Infants were 
Research in context
Evidence before this study
The licensure of the two currently available pneumococcal 
conjugate vaccines (PCVs), the ten-valent PCV (PCV10) and the 
13-valent PCV (PCV13), was based on demonstration of their 
immunological non-inferiority to seven-valent PCV. However, in 
itself, this non-inferiority does not preclude differences between 
these two second-generation PCVs. We searched PubMed from 
inception to Feb 28, 2019, using search terms including, but not 
limited to, “10-valent pneumococcal conjugate vaccine” OR 
“13-valent pneumococcal conjugate vaccine” AND 
“immunogenicity”. Two studies have been published on the 
comparative immunogenicity of PCV10 and PCV13: one from the 
Netherlands comparing the booster response in a 3 + 1 schedule, 
and a trial of a novel schedule at 1 months, 2 month, and 3 
months in Papua New Guinea. A further two European trials of 
investigational vaccines contained control groups that received 
PCV10 or PCV13 in a 3 + 1 schedule. These studies indicated that 
both vaccines are highly immunogenic. The vaccines differed little 
in terms of the proportions of children achieving protective levels 
of antibody, but differences in the geometric mean concentration 
of antibody were commonly observed and tended to favour 
PCV13, albeit with variations across the studies. Given the paucity 
of comparative data on PCV10 and PCV13, countries considering 
PCV introduction have little on which to base their decision, other 
than the relative cost of the vaccines. 
Added value of this study
This is the first published study to compare the two currently 
licensed PCVs in a 2 + 1 schedule—a schedule increasingly used 
by low-income and middle-income countries (LMICs), and one 
of the WHO-recommended schedules. The results of this study 
will therefore have importance in LMIC settings, which often 
have a high burden of pneumococcal disease. 
Implications of all the available evidence
The data from this randomised controlled trial in a LMIC 
support previous non-comparative data that both PCV10 and 
PCV13 are highly immunogenic in a 2 + 1 schedule, with similar 
reactogenicity. There are few differences between the two 
vaccines in relation to the 0·35 µg/mL correlate of protection, 
but the geometric mean concentrations of antibody, both 
post-primary series and post-booster, tend to be higher after 
vaccination with PCV13. It is hard to assess whether these 
differences would translate to differing degrees of protection 
afforded by the two vaccines, particularly for mucosal disease, 
in which a higher concentration of antibody might be required 
for protection. Vietnam and other LMICs considering vaccine 
introduction might wish to consider the immunological 
differences shown in this study in the context of their own 
pneumococcal epidemiology.
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excluded if they had any known allergy to any component 
of the vaccine or had had an allergic or anaphylactic 
reaction to any previous vaccine, had a known 
immunodeficiency disorder, or were born to a mother 
infected with HIV. Full details of the participant 
eligibility criteria and recruitment processes have been 
described previously.13
A parent or legal guardian of each participant provided 
written informed consent. The protocol was approved 
by the Institutional Review Board at the Pasteur Institute 
of Ho Chi Minh City, Vietnam, and ethical approval was 
obtained from the Human Research Ethics Committee 
of the Northern Territory Department of Health and 
Menzies School of Health Research, Australia, and the 
Ministry of Health Ethics Committee, Vietnam. The 
trial was overseen by an independent data safety and 
monitoring board. The protocol for this trial has been 
published elsewhere.13
Randomisation and masking
A computer-generated list of randomisation numbers 
was used in a block randomisation scheme, stratified by 
district, to allocate participants (in a 3:3:5:4:5:4 ratio) to 
one of six groups. This was a single-blind trial with all 
laboratory-based outcome assessors masked to the group 
allocation. Additional details of the randomisation and 
masking have been described previously.13
Procedures
Participants were assigned to receive one of six infant 
vaccination schedules: PCV10 in a 3 + 1 (group A), 3 + 0 
(group B), 2 + 1 (group C), or two-dose (group D) schedule; 
PCV13 in a 2 + 1 schedule (group E); or a control 
group (group F) that received no infant doses of PCV 
(figure 1). The control group was included to contribute 
data primarily for the secondary naso pharyngeal carriage 
outcomes, which will be presented elsewhere. Participants 
also received four doses of the hexavalent diphtheria, 
tetanus, pertussis, polio, Haemophilus influenzae type b, 
and hepatitis B (DTaP-IPV-Hib-HepB) vaccine. Partici-
pants in groups A–E provided four blood samples over 
the course of the trial. The timepoints for the collection of 
blood samples varied both between and within study 
groups to enable more questions to be addressed within 
the confines of a maximum of four blood samples per 
participant (see appendix for the full schedule of vaccines 
and samples). As such, the number of blood samples 
varied by timepoint, and samples from different PCV10 
study groups contributed to analyses of the comparative 
immunogenicity of PCV10 and PCV13 at different 
timepoints: pre-PCV from group A; 4 weeks after one 
dose of PCV from group D; post-primary series (4 weeks 
after two doses of PCV), pre-booster (at 9 months of age), 
and post-booster (4 weeks after a booster dose of PCV at 
9·5 months of age) from group C; and 18 months of age 
from a subset of group C (figure 1). We assessed 
the concentrations of serotype-specific IgG antibodies to 
all 13 serotypes in PCV13 using a modified third-
generation standardised ELISA.14 Functional antibody 
response to all 13 serotypes were also assessed by 
opsonophagocytic assay.15
Outcomes
To compare vaccination responses between PCV10 and 
PCV13, we planned to fully evaluate the immunogenicity of 
a 2 + 1 schedule (PCV10 or PCV13 given at 2 months, 
4 months, and 9·5 months of age) in a head-to-head 
manner. The primary outcome was the proportion of 
children with protective levels of antibody (defined as 
≥0·35 µg/mL, assessed by ELISA). GMCs of antibodies 
were also recorded. The primary outcome timepoint 
was 4 weeks post-primary series (age 5 months). At this 
timepoint, we also compared the two-dose primary series of 
PCV13 (group E) with a three-dose primary series of PCV10 
given at 2 months, 3 months, and 4 months of age (groups 
A and B). This comparison was listed in the protocol as the 
primary outcome because, at the time the trial was designed, 
the two-dose primary series was not an approved schedule 
for PCV10. Both comparisons are presented here. 
Secondary outcomes also included functional antibody 
responses to all 13 serotypes, assessed by opsonophagocytic 
assay. The proportion of children with an opsonisation 
index of at least 8 and geometric mean opsonisation 
indices were recorded in a subset of participants at 4 weeks 
post-primary series and 4 weeks post-booster.
The comparative reactogenicity of PCV10 and PCV13 
was also evaluated. Reactogenicity assessments included 
erythema at the PCV and DTaP-IPV-Hib-HepB vaccination 
sites and axillary temperature on days 0–4 post-vaccination, 
as measured by the parent or caregiver and recorded on a 
parent-held diary card.
A post-hoc analysis comparing the proportion of children 
with antibody concentrations of at least 1·00 µg/mL was 
done post-primary series and post-booster to explore 
whether the use of a higher threshold of protection would 
identify more differences between the vaccines.
Statistical analysis
The groups were primarily compared in terms of the 
proportions of children with a serotype-specific IgG 
concentration of at least 0·35 µg/mL at 4 weeks post-
primary series (the threshold used for comparing PCV 
formulations). For the head-to-head comparison of 
two-dose primary series of PCV10 and PCV13, a 10% risk 
difference was considered clinically significant. Risk 
differences (PCV10 – PCV13) with 95% CIs were cal-
culated with the Newcombe-Score method. The null 
hypothesis for each of the ten shared serotypes was that 
the risk difference was between –10% and 10%, with the 
null hypothesis rejected if the 95% CI of the risk 
difference was entirely outside of this range. An overall 
difference was considered demonstrated if at least seven 
of the ten individual null hypotheses were rejected in the 
same direction.
See Online for appendix
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152 allocated to group A 
(3+1 PCV10 at months 2, 
3, 4, and 9)
2-month blood draw 
(pre-PCV10)† 
101 scheduled for blood draw
100 followed up and 
analysed per protocol
1 withdrawn
51 not scheduled for blood 
draw 
5-month blood draw (after 
three doses of PCV10)
291 followed up
286 analysed per protocol
2 without sample
3 outside window
9 withdrawn
149 allocated to group B 
(3+0 PCV10 at months 
2, 3, and 4)
250 allocated to group C 
(2+1 PCV10 at months 
2, 4, and 9·5*)
202 allocated to group D 
(two-dose PCV10 at 
months 2 and 6)
251 allocated to group E 
(2+1 PCV13 at months 2, 
4, and 9·5*)
3-month blood draw (after 
one dose of PCV10)
201 followed up
197 analysed per protocol
4 without sample
1 withdrawn
3-month blood draw (after 
one dose of PCV13)
200 scheduled for blood draw
197 followed up
193 analysed per 
protocol
3 without sample
1 outside window
3 withdrawn
51 not scheduled for blood 
draw
5-month blood draw (after 
two doses of PCV10)
244 followed up
237 analysed per protocol
4 without sample
3 outside window
6 withdrawn
Opsonophagocytic assay‡
124 analysed per protocol 
1 outside window
5-month blood draw (after 
two doses of PCV13)
240 followed up
232 analysed per protocol
4 without sample
4 outside window
8 withdrawn
Opsonophagocytic assay‡
124 analysed per protocol
1 outside window
9-month blood draw 
(pre-booster of PCV10)
241 followed up 
236 analysed per protocol
5 without sample
3 withdrawn
9-month blood draw 
(pre-booster of PCV13)
235 followed up
228 analysed per protocol
7 without sample
5 withdrawn
10-month blood draw 
(post-booster of PCV10)
235 followed up
226 analysed per protocol
4 without sample
5 outside window
6 withdrawn
Opsonophagocytic assay‡
121 analysed per protocol
4 outside window
10-month blood draw 
(post-booster of PCV13)
231 followed up
221 analysed per protocol
3 without sample
7 outside window
4 withdrawn
Opsonophagocytic assay‡
120 analysed per protocol
5 outside window
18-month blood draw§ 
50 scheduled for blood draw 
48 followed up 
47 analysed
1 without sample
2 withdrawn
200 not scheduled for blood 
draw
18-month blood draw§ 
51 scheduled for blood draw 
46 followed up and 
analysed
5 withdrawn
200 not scheduled for blood 
draw
197 allocated to group F 
(control, no infant PCV; 
PCV10 given at
months 18 and 24)
185 followed up at
18 months
12 withdrawn
1201 randomly allocated 
1424 infants screened
223 excluded
137 declined to participate
48 met exclusion criteria
38 other reasons
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The two-dose primary series of PCV13 and the three-
dose primary series of PCV10 were compared in terms of 
non-inferiority, based on a non-inferiority margin of a 
10% risk difference, as used by regulatory authorities. 
The null hypothesis for each of the shared serotypes was 
that the risk difference was greater than 10%, with the 
null hypothesis rejected if the upper bound of the 90% CI 
was less than 10% (equivalent to using a 5% one-sided 
test). An overall conclusion of non-inferiority was drawn 
if the null hypotheses were rejected for at least seven of 
the ten shared serotypes.
The sample size provided 98% power for an overall 
conclusion on the difference between two doses of PCV10 
and PCV13, and more than 99% power for an overall 
conclusion on the non-inferiority of two doses of PCV13 
compared with three doses of PCV10. Details of the 
sample size calculations have been described previously.13
IgG concentrations between groups were also compared 
in terms of GMC ratios (PCV10 / PCV13) with 95% CIs, 
and were described as higher in one group if the 95% CI 
excluded a ratio of 1·00. Similarly, geometric mean 
opsonisation indexes were described as higher in one 
group if the 95% CI of the ratio of geometric mean 
opsonisation indexes (PCV10 / PCV13) excluded a ratio of 
1·00. Risk differences were calculated for the proportion 
of children with an opsonisation index of at least 8, with a 
10% difference considered significant, in line with the IgG 
comparisons. Beyond the primary outcome, our aim was 
to provide an overall description of the pattern of 
differences in immunogenicity between PCV10 and 
PCV13. As such, no formal adjustments for multiple 
comparisons were made, but we have deliberately avoided 
reporting p values. Comparisons of reactogenicity 
(proportions of participants with erythema or fever) 
between groups were done with Fisher’s exact tests.
Statistical analyses were done in accordance with the 
protocol and the statistical analysis plan. All immuno-
logical analyses were done on the per-protocol population, 
and primary analyses were repeated on the intention-to-
treat population. Reactogenicity analyses were done on 
the intention-to-treat population. Analyses were done 
using Stata statistical software (release 14).
The trial is registered at ClinicalTrials.gov, number 
NCT01953510.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
1424 infants were screened between Sept 30, 2013, and 
Jan 9, 2015, with 1201 (84%) enrolled (figure 1): 152 (13%) 
to group A, 149 (12%) to group B, 250 (21%) to group C, 
202  (17%) to group D, 251 (21%) to group E, and 197 
(16%) to group F. The groups were balanced with respect 
to baseline characteristics (table 1). Overall, 1179 
(98%) par ticipants completed their primary series 
vaccinations, 1146 (95%) received their booster dose of 
PCV or were followed up to 9 months of age, and 
Figure 1: Trial profile
Samples collected outside the visit window (27–43 days post-vaccination) were 
included only in the intention-to-treat analyses. The most common reason 
for participants to be without a blood sample was that the nurse was unable to 
successfully find a vein (18 [49%] of 37 missing blood draws). 
PCV=pneumococcal conjugate vaccine. PCV10=ten-valent PCV.  
PCV13=13-valent PCV. *PCV (and the hexavalent diphtheria, tetanus, pertussis, 
polio, Haemophilus influenzae type b, and hepatitis B [DTaP-IPV-Hib-HepB] 
vaccine) were administered at 9·5 months in participants from groups C and E 
because the Vietnamese Ministry of Health does not permit co-administration 
of measles and DTaP-IPV-Hib-HepB (see appendix for full schedules of PCV and 
co-administered vaccines). †The 2-month blood sample from group A provided 
pre-PCV data; samples at this timepoint were only collected from one study 
group, with the assumption that all groups would be interchangeable at 
baseline as a result of randomisation. ‡125 participants from groups C and E 
contributed to the opsonophagocytic assay analyses, selected as the first 
125 with both post-primary series and post-booster blood samples collected. 
§Participants allocated to groups A–E from the last 300 recruited provided a 
blood sample at 18 months of age, with the remainder providing a sample at an 
alternative timepoint (appendix).
Group A 
(n=152)
Group B 
(n=149)
Group C 
(n=250)
Group D 
(n=202)
Group E 
(n=251)
Group F 
(n=197)
Sex
Male 66 (43%) 73 (49%) 135 (54%) 91 (45%) 127 (51%) 100 (51%)
Female 86 (57%) 76 (51%) 115 (46%) 111 (55%) 124 (49%) 97 (49%)
District
4 68 (45%) 67 (45%) 112 (45%) 90 (45%) 111 (44%) 87 (44%)
7 84 (55%) 82 (55%) 138 (55%) 112 (55%) 140 (56%) 110 (56%)
Birthweight, 
g*
3234 (424) 3212 (349) 3228 (370) 3234 (410) 3199 (357) 3208 (395)
Place of delivery
Hospital 149 (98%) 149 (100%) 245 (98%)† 194 (96%) 247 (99%)† 192 (97%)
Other 3 (2%) 0 4 (2%) 8 (4%) 3 (1%) 5 (3%)
Type of delivery
Normal 89 (59%) 85 (57%) 160 (64%) 130 (64%) 151 (60%) 121 (61%)
Elective 
caesarean
30 (20%) 30 (20%) 43 (17%) 36 (18%) 57 (23%) 34 (17%)
Emergency 
caesarean
27 (18%) 30 (20%) 40 (16%) 34 (17%) 42 (17%) 41 (21%)
Other or 
unknown
6 (4%) 4 (3%) 7 (3%) 2 (1%) 1 (0·4%) 1 (1%)
Cigarette smoker at residence
No 57 (38%) 52 (35%) 81 (33%)† 74 (37%) 86 (34%) 72 (37%)
Yes 95 (63%) 97 (65%) 168 (67%) 128 (63%) 165 (66%) 125 (63%)
Breastfeeding at enrolment
No 41 (27%)† 42 (28%) 55 (22%) 37 (18%) 56 (22%)† 56 (29%)†
Yes 110 (73%) 107 (72%) 195 (78%) 165 (82%) 194 (78%) 140 (71%)
Data are n (%) or mean (SD). *Birthweight data missing for ten participants (one from group B, three from group C, 
three from group D, two from group E, and one from group F). †Data missing for one participant.
Table 1: Baseline characteristics by study group
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1093 (91%) were followed up to 18 months of age. Of the 
108 participants withdrawn before 18 months, the 
reasons for withdrawal were: moved away and lost to 
follow-up (55 [51%]); refused a study procedure (23 [21%]); 
voluntary withdrawal (22 [20%]); and other (eight [8%]).
At 5 months of age, among the 237 (95%) participants 
in group C (PCV10) and 232 (92%) in group E (PCV13) 
who completed the primary vaccination series and had 
blood draws within the specified time window (figure 1), 
the head-to-head comparison of two doses PCV13 and 
two doses of PCV10 showed no evidence of a difference 
in the proportion of infants with a serotype-specific IgG 
concentration of at least 0·35 μg/mL, with the CIs for 
the between-group differences overlapping with the 
–10% to 10% range for all ten shared serotypes (table 2, 
figure 2). In both groups, more than 95% of participants 
had protective IgG concentrations for all serotypes 
except 6B and 23F. Comparing the magnitude of the 
response on the basis of GMC ratio, GMCs were higher 
in the PCV10 group than in the PCV13 group for 
serotypes 6B and 19F, and higher in the PCV13 
group than in the PCV10 group for the other eight 
shared serotypes (table 2).
We also showed that two doses of PCV13 were non-
inferior to three doses of PCV10 in terms of the 
proportion of infants with protective serotype-specific 
IgG concentrations, with the upper bound of the CI for 
the between-group difference less than 10% for nine of 
the ten shared serotypes (table 2, figure 2). The point 
estimates for the risk differences for these nine 
serotypes were all within –2% and 2%. The exception 
was serotype 6B, for which the proportion of participants 
achieving a protective IgG concentration was 84·6% 
(95% CI 79·9–88·6) in the PCV10 group compared with 
61·2% (54·6–67·5) in the PCV13 group (risk difference 
23·4% [90% CI 17·0–29·6]). IgG GMCs were higher in 
the PCV10 group than in the PCV13 group for serotypes 
6B, 14, and 18C, and higher in the PCV13 group than in 
the PCV10 group for serotypes 1, 4, 5, and 9V. The 
conclusions based on the results of the per-protocol 
analysis and the intention-to-treat analysis did not 
differ (appendix).
Participants with IgG concentration ≥0·35 μg/mL, 
% (95% CI)
Risk difference, 
%
GMC, μg/mL 
(95% CI)
GMC ratio 
(95% CI)
Two-dose 
PCV10 (n=237)
Three-dose 
PCV10 (n=286)
Two-dose 
PCV13 (n=232)
Two-dose PCV10 
minus PCV13 
(95% CI)
Three-dose 
PCV10 minus 
PCV13 (90% CI)
Two-dose 
PCV10 (n=237)
Three-dose 
PCV10 (n=286)
Two-dose 
PCV13 (n=232)
Two-dose 
PCV10 / PCV13
Three-dose 
PCV10 / PCV13
Shared PCV serotypes
1 97·9 
(95·1 to 99·3)
98·3 
(96·0 to 99·4)
100·0 
(98·4 to 100·0)
–2·1 
(–4·8 to –0·1)
–1·7 
(–3·5 to –0·3)
2·21 
(1·97 to 2·48)
2·79 
(2·51 to 3·10)
4·88 
(4·40 to 5·42)
0·45 
(0·39 to 0·53)
0·57 
(0·49 to 0·66)
4 98·7 
(96·3 to 99·7)
99·0 
(97·0 to 99·8)
100·0 
(98·4 to 100·0)
–1·3 
(–3·7 to 0·6)
–1·0 
(–2·6 to 0·3)
3·21 
(2·87 to 3·58)
3·85 
(3·44 to 4·31)
4·82 
(4·41 to 5·26)
0·67 
(0·58 to 0·77)
0·80 
(0·69 to 0·93)
5 95·8 
(92·4 to 98·0)
98·6 
(96·5 to 99·6)
99·1 
(96·9 to 99·9)
–3·4 
(–6·8 to –0·4)
–0·5 
(–2·3 to 1·3)
1·17 
(1·07 to 1·27)
1·81 
(1·67 to 1·97)
2·20 
(2·00 to 2·41)
0·53 
(0·47 to 0·60)
0·83 
(0·73 to 0·94)
6B 76·8 
(70·9 to 82·0)
84·6 
(79·9 to 88·6)
61·2 
(54·6 to 67·5)
15·6 
(7·2 to 23·7)
23·4 
(17·0 to 29·6)
0·80 
(0·69 to 0·92)
1·08 
(0·95 to 1·23)
0·48 
(0·42 to 0·55)
1·65 
(1·36 to 1·99)
2·24 
(1·86 to 2·69)
7F 98·7 
(96·3 to 99·7)
99·3 
(97·5 to 99·9)
100·0 
(98·4 to 100·0)
–1·3 
(–3·7 to 0·6)
–0·7 
(–2·1 to 0·5)
2·07 
(1·89 to 2·27)
3·04 
(2·79 to 3·32)
3·33 
(3·05 to 3·63)
0·62 
(0·55 to 0·71)
0·91 
(0·81 to 1·03)
9V 96·2 
(92·9 to 98·2)
99·3 
(97·5 to 99·9)
97·8 
(95·0 to 99·3)
–1·6 
(–5·1 to 1·7)
1·5 
(–0·3 to 3·7)
1·63 
(1·47 to 1·81)
2·47 
(2·26 to 2·71)
3·27 
(2·93 to 3·65)
0·50 
(0·43 to 0·58)
0·76 
(0·66 to 0·87)
14 98·3 
(95·7 to 99·5)
100·0 
(98·7 to 100·0)
98·3 
(95·6 to 99·5)
0·0 
(–2·7 to 2·9)
1·7 
(0·4 to 3·8)
5·86 
(5·11 to 6·73)
9·76 
(8·79 to 10·83)
7·99 
(6·82 to 9·37)
0·73 
(0·60 to 0·90)
1·22 
(1·02 to 1·47)
18C 96·6 
(93·5 to 98·5)
98·6 
(96·5 to 99·6)
98·7 
(96·3 to 99·7)
–2·1 
(–5·3 to 0·9)
–0·1 
(–2·0 to 1·9)
1·86 
(1·64 to 2·11)
3·87 
(3·47 to 4·30)
3·14 
(2·84 to 3·48)
0·59 
(0·50 to 0·70)
1·23 
(1·06 to 1·43)
19F 99·2 
(97·0 to 99·9)
99·7 
(98·1 to 100·0)
99·1 
(96·9 to 99·9)
0·0 
(–2·2 to 2·3)
0·5 
(–0·8 to 2·2)
9·54 
(8·37 to 10·87)
8·34 
(7·52 to 9·24)
7·67 
(6·78 to 8·68)
1·24 
(1·04 to 1·49)
1·09 
(0·93 to 1·27)
23F 77·6 
(71·8 to 82·8)
90·6 
(86·6 to 93·7)
89·2 
(84·5 to 92·9)
–11·6 
(–18·2 to –4·9)
1·3 
(–3·0 to 5·9)
0·89 
(0·78 to 1·02)
1·32 
(1·18 to 1·48)
1·14 
(1·01 to 1·29)
0·78 
(0·65 to 0·94)
1·16 
(0·98 to 1·37)
Additional PCV13 serotypes
3 5·9 
(3·3 to 9·7)
7·0 
(4·3 to 10·6)
97·8 
(95·0 to 99·3)
–91·9 
(–94·6 to –87·3)
–90·9 
(–93·2 to –87·2)
0·10 
(0·09 to 0·11)
0·11 
(0·10 to 0·12)
1·53 
(1·40 to 1·68)
0·07 
(0·06 to 0·08)
0·07 
(0·06 to 0·08)
6A 40·5 
(34·2 to 47·1)
50·3 
(44·4 to 56·3)
94·8 
(91·1 to 97·3)
–54·3 
(–60·8 to –47·0)
–44·5 
(–49·7 to –38·8)
0·31 
(0·28 to 0·35)
0·37 
(0·34 to 0·41)
1·94 
(1·69 to 2·21)
0·16 
(0·14 to 0·19)
0·19 
(0·16 to 0·22)
19A 70·5 
(64·2 to 76·2)
68·2 
(62·4 to 73·5)
98·3 
(95·6 to 99·5)
–27·8 
(–34·0 to –21·8)
–30·1 
(–34·9 to–25·3)
0·55 
(0·49 to 0·62)
0·56 
(0·51 to 0·62)
3·82 
(3·34 to 4·36)
0·14 
(0·12 to 0·17)
0·15 
(0·12 to 0·17)
Immunogenicity data at 4 weeks after two doses of PCV10 (at 2 months and 4 months of age, group C), two doses of PCV13 (at 2 months and 4 months of age, group E), or three doses of PCV10 (at 2 months, 
3 months, and 4 months of age, groups A and B). GMC=geometric mean concentration. PCV10=ten-valent pneumococcal conjugate vaccine. PCV13=13-valent pneumococcal conjugate vaccine. 
Table 2: Post-primary series immunogenicity in the per-protocol population
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In addition to the post-primary series timepoint, we 
directly compared responses to PCV10 and PCV13 at 
4 weeks after a single dose, pre-booster, 4 weeks post-
booster, and 18 months of age (figure 3, appendix). At 
2 months of age, pre-PCV, the highest GMCs of anti-
body were seen for serotypes 14 (0·64 μg/mL [95% CI 
0·49 to 0·84]), 19F (0·45 μg/mL [0·39 to 0·53]), 
19A (0·41 μg/mL [0·36 to 0·47]), and 6A (0·32 μg/mL 
[0·28 to 0·37]), and the proportion of participants with 
IgG concentrations of at least 0·35 μg/mL for these 
four serotypes ranged from 44·0% (95% CI 34·1 to 
54·3), for serotype 6A, to 68·0% (57·9 to 77·0), for 
serotype 14 (appendix). Comparing pre-PCV and post-
PCV GMCs, a single dose of either PCV10 or PCV13 
elicited no response to the shared serotypes 6B, 14, and 
23F, or to the non-PCV10 types 6A and 19A. After a 
single dose of either PCV10 or PCV13, more than half 
of participants had IgG concentrations of at least 0·35 
μg/mL to serotypes 1, 4, 5, 7F, 14, and 19F in 
both groups, and to serotype 18C in the PCV13 
group. Considering a 10% difference in the proportion 
of participants with IgG concentrations of at least 0·35 
μg/mL as clinically significant, more partici pants had 
protective concen trations of IgG specific to serotype 19F 
in the PCV10 group than in the PCV13 group (risk 
difference 18·3% [11·4 to 25·2]), and more to serotype 
18C in the PCV13 group than in the PCV10 group (risk 
difference –33·0% [–41·7 to –23·6]; appendix). Com-
paring the magnitude of the response (based on the 
ratio of GMCs for the ten shared serotypes), GMCs were 
higher in the PCV10 group for serotypes 1, 4, 5, 9V, and 
19F, and higher in the PCV13 group for serotypes 7F 
and 18C (appendix).
At 9 months of age, pre-booster and 5 months post-
primary series, most participants still had protective 
concentrations of antibody to most of the ten shared 
serotypes, ranging from 75·4% (69·4 to 80·8) to 100·0% 
[98·4 to 100·0] in the PCV10 group, and 68·9% (62·4 to 
74·8) to 99·1% (96·9 to 99·9) in the PCV13 group. The 
proportion of participants with protective concentrations 
of serotype-specific antibody was higher in the PCV10 
group than in the PCV13 group for serotype 6B (risk 
difference 18·6% [12·4 to 24·9]), and higher in the PCV13 
group than in the PCV10 group for serotype 5 (risk 
difference –18·4% [–24·8 to –12·0]). GMCs were higher 
in the PCV10 group for serotypes 6B, 18C, 19F, and 23F, 
and higher in the PCV13 group for serotypes 1, 5 and 7F, 
9V, and 14 (appendix).
Post-booster, the proportion of participants with IgG 
concentrations of at least 0·35 μg/mL was more than 97% 
for all ten shared serotypes in both groups (appendix). In 
terms of GMCs, the same pattern was seen post-booster 
dose as post-primary series for most serotypes, with 
GMCs higher in the PCV10 group than in the PCV13 
group for serotype 19F, and higher in the PCV13 
group than in the PCV10 group for serotypes 1, 5, 7F, 9V, 
14, and 23F. By contrast with the post-primary series 
results, post-booster GMCs were higher in the PCV10 
group than in the PCV13 group for serotype 18C, and 
higher in the PCV13 group than in the PCV10 group for 
serotype 6B, with no difference between groups for 
serotype 4 (appendix).
At 18 months of age, the proportion of participants with 
protective IgG concentrations was still greater than 95% 
for serotypes 14 and 19F (both groups) and serotype 6B 
(PCV10 group), and greater than 59% for all other shared 
serotypes, with no between-group differences at the 
10% level (appendix). Differences in GMCs were only 
seen for serotypes 18C and 19F, which showed higher 
concentrations in the PCV10 group than in the PCV13 
group (appendix).
For the non-PCV10 serotypes (3, 6A, and 19A), IgG 
concentrations of at least 0·35 μg/mL were seen in more 
than 94% of PCV13 recipients post-primary series 
(table 2), and more than 99% of PCV13 recipients post-
booster (appendix). The GMC to serotype 3 was similar 
post-primary series (table 2) and post-booster (appendix) 
whereas GMCs for serotypes 6A and 19A increased 
substantially. PCV10 also elicited responses to serotypes 
6A and 19A post-booster, with more than 90% 
of participants achieving IgG concentrations of at least 
0·35 μg/mL (appendix). GMCs to all three non-PCV10 
serotypes were higher in the PCV13 group than in the 
PCV10 group at all timepoints, with the exception of 
serotype 6A at 3 months of age (4 weeks post-one PCV 
dose) and serotype 19A at 18 months of age, for which 
there were no differences between the vaccine groups 
(appendix). The proportion of infants with serotype-
specific IgG concentrations of at least 1·00 μg/mL were 
Figure 2: Comparative immunogenicity of PCV13 versus PCV10 at 4 weeks post-primary series
Data are differences (PCV10 minus PCV13) in the proportions of patients with protective serotype-specific IgG 
concentrations (≥0·35 μg/mL) in patients who received PCV13 versus those who received PCV10. (A) Two-dose 
primary series of PCV13 (at 2 months and 4 months; group E) versus two-dose primary series of PCV10 
(at 2 months and 4 months; group C). (B) Two-dose primary series of PCV13 (group E) versus three-dose primary 
series of PCV10 (at 2 months, 3 months, and 4 months; groups A and B). Bars represent 95% CIs for two-sided 
tests of difference (A) or 90% CIs for one-sided tests of non-inferiority (B), with solid vertical lines indicating the 
predefined thresholds for determining differences or non-inferiority between groups. PCV10=ten-valent 
pneumococcal conjugate vaccine. PCV13=13-valent pneumococcal conjugate vaccine.
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also compared post-primary series and post-booster 
(appendix). Post-primary series, more participants in the 
PCV13 group than in the PCV10 group had protective 
antibody concentrations for serotypes 1 and 5, and more 
participants in the PCV10 group than in the PCV13 group 
had protective concentrations for serotype 6B at the 10% 
level. Post-booster, more participants in the PCV13 group 
than in the PCV10 group had protective concentrations 
for serotype 5.
Differences in opsonophagocytic responses after the 
primary series of PCV10 or PCV13 vaccinations (table 3) 
broadly reflected those seen in the IgG concentrations. 
Geometric mean opsonisation indices were higher in the 
PCV10 group than in the PCV13 group for serotypes 6B 
and 19F, and higher in the PCV13 group than in the PCV10 
group for all other serotypes except 14 (based on the ratio 
of geometric mean opsonisation indexes for the ten shared 
serotypes). The proportions of participants with an 
opsonisation index of 8 or more (table 3) also reflected the 
proportions of those with protective IgG concentrations 
for most serotypes, albeit with some exceptions: for 
serotype 1, more than 97% of infants in both groups had 
protective IgG concentrations (table 2), whereas the 
proportions achieving an opsonisation index of 8 or more 
were 66·1% (57·1–74·4) in the PCV10 group and 87·9% 
(80·8–93·1) in the PCV13 group (table 3). A similar pattern 
was seen for serotype 9V in the PCV10 group, with only 
80·6% (72·6–87·2) achieving an opsonisation index of at 
least 8, compared with 96·2% (92·9–98·2) having a 
protective IgG concentration. Only serotypes 1 and 9V had 
differences between the PCV10 and PCV13 groups at the 
10% level, with higher proportions of patients in the PCV13 
group having opsonisation indices of 8 or more (table 3).
There were fewer between-group differences post-
booster than post-primary series (table 3). Geometric mean 
opsonisation indices were higher in the PCV10 group than 
in the PCV13 group for serotype 19F, and higher in the 
PCV13 group than in the PCV10 group for serotypes 4, 6B, 
7F, 9V, and 23F based on the ratio of geometric mean 
opsonisation indices. More than 90% of participants in 
both groups achieved an opsonisation index of at least 8 for 
the ten shared serotypes, including serotype 1, with no 
differences between groups at the 10% level.
PCV13 was immunogenic to each of the non-PCV10 
serotypes after the primary series, with more than 
92% of participants achieving an opsonisation index of at 
least 8, and increased responses were seen following 
the booster dose for serotypes 6A and 19A (table 3). As 
with the IgG responses, PCV10 generated little to 
no functional immunity for serotypes 3, 6A, and 19A 
Figure 3: Serotype-specific IgG concentrations before and after PCV10 or PCV13 vaccinations
GMCs of serotype-specific IgG (lines) and proportion of participants with protective concentrations (≥0·35 μg/mL) of serotype-specific IgG (bars) over time, for the ten shared serotypes and the 
three additional serotypes in PCV13, with 95% CIs. Sources of data were as follows: group A at 2 months of age (pre-PCV); group D (PCV10) and group E (PCV13) at 3 months of age (after one dose); 
and group C (PCV10) and group E (PCV13) at 5 months (after two-dose primary series), 9 months (pre-booster), 10 months (post-booster), and 18 months of age (in a subset of participants). 
GMC=geometric mean concentration. PCV10=ten-valent pneumococcal conjugate vaccine. PCV13=13-valent pneumococcal conjugate vaccine.
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post-primary series, but substantial opsonophagocytic 
responses to serotypes 6A and 19A were seen after the 
booster dose of PCV10 (table 3).
Reactogenicity information was analysed at 2 months, 
4 months, and 9·5 months of age in the 2 + 1 PCV10 
group (group C) and the 2 + 1 PCV13 group (group E), and 
at 2 months and 4 months of age in the control 
group (group F; table 4). Diary cards were collected from 
more than 96% of participants vaccinated at each 
timepoint. The incidences of erythema at the PCV and 
the DTaP-IPV-Hib-HepB vaccination sites were both low. 
The incidence of erythema at the PCV site did not differ 
between the PCV10 and PCV13 groups at any timepoint 
(p=0·395 at 2 months, p=0·939 at 4 months, and p=0·346 
at 9·5 months), and was similar to that at the DTaP-IPV-
Hib-HepB site. Co-administration of DTaP-IPV-Hib-
HepB with either PCV10 or PCV13 had no effect on the 
incidence of erythema at the DTaP-IPV-Hib-HepB site 
(p=0·590 at 2 months, p=0·100 at 4 months, and p>0·999 
at 9·5 months; table 4).
The incidence of axillary fever (≥37·5°C) following PCV 
vaccination ranged from 39% to 44% (4–10% for severe 
fever [≥38·5°C]; table 4). Fever and severe fever did not 
differ in incidence between PCV10 recipients and PCV13 
recipients at any timepoint (p=0·880 at 2 months, 
p=0·190 at 4 months, and p=0·643 at 9·5 months). In the 
PCV13 group, the proportion of fevers categorised as 
severe at 4 months and at 9·5 months was higher than 
that at 2 months (p=0·019). The incidence of fever after 
co-administration of PCV and DTaP-IPV-Hib-HepB was 
significantly higher than the incidence after DTaP-IPV-
Hib-HepB vaccination alone (p<0·0001 at 2 months and 
at 4 months).
135 participants from groups A–F were hospitalised 
during the trial, in a total of 163 admissions (appendix). 
The most common reasons for hospitalisation were acute 
respiratory infection (70 [43%] of 163) and acute gastro-
enteritis (29 [18%]). 156 (94%) hospitalisations were 
unrelated to vaccination, and all resolved without 
sequelae. The reasons for hospitalisation (p=0·750) and 
the causality (in relation to vaccination; p=0·098) were 
similar across groups (appendix). No participants were 
withdrawn as a result of harms, and none died during 
the trial.
Discussion
PCVs are now in use in national immunisation 
programmes in 142 countries. Increasingly, countries are 
adopting a 2 + 1 schedule, with a two-dose primary series 
followed by a booster dose at or after 9 months of age. In 
this paper we present the results of the first head-to-head 
study comparing the two currently available PCVs in a 
2 + 1 schedule, measuring both serotype-specific IgG and 
functional antibody levels to all 13 serotypes in PCV13. 
The immunological advantage of one vaccine over the 
other varied by serotype and by timepoint. The overall 
pattern that emerges is that PCV10 generally fares better 
for the shared serotypes after a single dose. After the two-
dose primary series, responses to PCV13 are stronger, 
but wane similarly to PCV10 by 9 months of age. PCV13 
produces stronger booster responses, but this effect is 
lost by 18 months of age.
Responses after a single dose allow us to judge 
protection in the interval between doses. This knowledge 
is important because many children will not present on 
time for the second dose, and because 1 + 1 schedules are 
currently under consideration.16 After a single dose of 
either PCV10 or PCV13, there was no response to some 
serotypes (6B, 14, and 23F, and non-PCV10 types 6A and 
19A). However, for most other serotypes, the majority of 
2 months 4 months 9·5 months
N Any Severe* N Any Severe* N Any Severe*
Erythema
At PCV10 site 244 23 (9%) 2 (1%) 235 26 (11%) 1 (<1%) 218 19 (9%) 1 (<1%) 
At PCV13 site 237 17 (7%) 0 222 23 (10%) 1 (<1%) 211 12 (6%) 0 
At DTaP-IPV-Hib-HepB site
PCV10 group 244 13 (5%) 2 (1%) 236 21 (9%) 1 (<1%) 222 13 (6%) 1 (<1%) 
PCV13 group 240 18 (8%) 1 (<1%) 225 29 (13%) 0  211 11 (5%) 0 
Control group 192 11 (6%) 0 188 15 (8%) 2 (1%) NA NA NA
Fever
PCV10 and DTaP-IPV-Hib-HepB 237 104 (44%) 10 (4%) 235 102 (43%) 11 (5%) 225 87 (39%) 16 (7%) 
PCV13 and DTaP-IPV-Hib-HepB 236 98 (42%) 9 (4%) 227 100 (44%) 20 (9%) 219 89 (41%) 21 (10%) 
DTaP-IPV-Hib-HepB alone 186 35 (19%) 3 (2%) 187 18 (10%) 4 (2%) NA NA NA
Data are n (%) and show participants reporting erythema at the vaccination site(s) and participants reporting axillary fever after vaccination at various timepoints among 
participants for whom data were available (N). 1809 diary cards were collected, of which 20 were excluded because they contained no data on erythema or fever. Otherwise, 
all available data contributed to the analysis. The maximum reported values for erythema and fever across days 0–4 were used. PCV10=ten-valent pneumococcal conjugate 
vaccine. PCV13=13-valent pneumococcal conjugate vaccine. DTaP-IPV-Hib-HepB=hexavalent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis 
B vaccine. NA=Not applicable. *Severe erythema was defined by a diameter of more than 30 mm, and severe fever was defined as a temperature of 38·5°C or higher. 
Table 4: Reactogenicity
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children responded beyond the protective concentration 
of 0·35 µg/mL, consistent with the observation that 
there is some incomplete protection afforded to infants 
by a single dose. The magnitude of the response was 
greater with PCV10 for half of the shared serotypes.
Both vaccines produced strong responses post-primary 
series, with more than 95% of children responding 
to most serotypes (the exceptions being 6B and 23F, 
consistent with previous findings17,18), although the mag-
nitude of the response was greater with PCV13 for eight 
of the shared serotypes. After the booster, almost all 
children had protective levels of antibody, but again the 
magnitude of the response was greater with PCV13 for 
seven of the shared serotypes. The concentration of 
0·35 µg/mL was determined from a pooled analysis of 
data from efficacy trials, and was established as the basis 
for comparing new with existing PCVs post-primary 
series.19 The true protective concentration of antibody 
varies geographically, by serotype, and by disease type.20–22 
Applying a more conservative concentration threshold of 
1·00 μg/mL to our data, more than 80% of children 
responded to most serotypes post-primary series (the 
exceptions being serotypes 6B and 23F in both groups, 
and 5 in the PCV10 group), and more than 90% post-
booster (the only exception being serotype 5 in the PCV10 
group). At this threshold, PCV13 fared better for serotypes 
1 (post-primary) and 5 (both post-primary and post-
booster), and PCV10 for serotype 6B (post-primary).
In general, the opsonophagocytic assay titres reflected 
the ELISA titres, with similar proportions of infants 
protected by an IgG concentration of at least 0·35 μg/
mL and infants with an opsonisation index of at least 8, 
but some important differences did emerge. With both 
vaccines, particularly PCV10, poor opsonophagocytic 
assay responses to serotype 1 were seen post-primary 
series, despite strong ELISA responses. This finding 
was reflected in the two European trials of investigational 
PCVs, in which 41% and 62% of participants in the 
PCV10 groups and 61% and 84% in the PCV13 groups 
had an opsonisation index of at least 8.9,10 This disconnect 
between responses measured by opsonophagocytic 
assay and by ELISA is corrected after the booster dose, 
providing immunological evidence for the importance 
of a booster dose in protecting against disease. This is 
an important finding for Africa, where serotype 1 is a 
frequent cause of pneumococcal disease,23 and where 
most countries use a 3 + 0 schedule without a booster 
dose. Analysis of serotype 1 immuno genicity in the 
context of reduced-dose PCV10 schedules with or 
without a booster will be reported elsewhere as part of 
the evaluation of different PCV schedules (the other aim 
of this trial).
Both vaccines were strongly immunogenic against 
serotype 19F; however, responses were stronger after 
PCV10 vaccination at all timepoints and according to 
both ELISA and opsonophagocytic assay. By contrast, 
findings from the Dutch study11 showed that PCV13 
produced stronger 19F booster responses by ELISA than 
did PCV10, although opsonophagocytic assay responses 
were similar. Serotype 19F has persisted in both carriage24 
and disease25 in the USA, despite more than 15 years of 
vaccination, and has been the most common cause of 
vaccine failure in children.26 In the original PCV7 efficacy 
trial,27 effectiveness against invasive pneumococcal 
disease and ear disease for serotype 19F was lower than 
for other serotypes (along with serotype 6B), despite good 
circulating antibody levels. The sharp rise in serotype 
19A disease after PCV7 introduction shows that the 19F 
component of PCV7 (and PCV13) provides no protection 
against 19A disease. By contrast, the 19F component of 
PCV10 appears to provide protection against 19A disease, 
although probably not carriage.28,29
PCV13 elicited strong responses to the non-PCV10 
serotypes, with more than 94% of children responding 
post-primary series and more than 99% post-booster. 
Interestingly, PCV13 produced only modest increases in 
IgG and opsonophagocytic assay responses for serotype 
3 post-booster compared with post-primary series, and 
these responses were considerably lower than those 
for other serotypes, a finding consistent with previous 
immunogenicity data.18 The effectiveness of PCV13 
against serotype 3 disease is in doubt.30,31 Among PCV10 
recipients, we found modest immunogenicity to sero-
types 6A and 19A after the booster dose at 9 months, 
with more than 90% of children achieving an IgG 
concentration of at least 0·35 μg/mL, although the 
GMCs were significantly lower than those generated by 
PCV13. Opsonophagocytic assay responses were also 
lower but considerable. These results support findings 
from three experimental PCVs in the 1990s showing 
poor correlation between ELISA and opsonophagocytic 
assay results for cross-reactive serotypes,32 but are 
consistent with some degree of protection afforded by 
PCV10 against both 6A and 19A disease. As part of this 
trial, we are evaluating the effects of vaccination on 
pneumococcal carriage, which will elucidate the capacity 
for PCV10 to protect against carriage of serotypes 6A 
and 19A.
One of the limitations of this study was the use of 
immunological endpoints rather than disease outcomes. 
However, given that both PCV10 and PCV13 have been 
in routine use in many countries for several years with 
demonstrated effectiveness, a direct comparison of the 
two vaccines on this basis is appropriate, and is enhanced 
by the inclusion of functional opsonophagocytic assays 
in addition to the standard IgG antibody measurement 
by ELISA. Another limitation is the inclusion of 
assessment of responses to multiple serotypes at several 
timepoints, leading to the likelihood that some of the 
observed differences arose by chance. This is a problem 
faced by all studies of PCVs. To compensate for this, we 
defined a single conclusion for the primary outcome, 
requiring a difference (or non-inferiority) in the 
proportion of part icipants with an IgG concentration of 
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at least 0·35 µg/mL to be observed for seven of the ten 
shared serotypes. Beyond the primary outcome, no 
formal adjustments for multiple comparisons were 
made. The inclusion of multiple outcomes in this study 
is also a strength. We have assessed the immunogenicity, 
with both ELISAs and opsonophagocytic assays, and 
reactogenicity of PCV10 and PCV13 in a 2 + 1 schedule, 
providing a comprehensive head-to-head comparison 
of these vaccines. For the reactogenicity assessments, a 
limitation of this study is the use of parent-held diary 
cards. However, the same potential issues of bias in self-
reported symptoms apply to all study groups, and 
therefore would not affect the between-group comparisons. 
Furthermore, we reported a single measure for the 
occurrence of erythema and fever on days 0–4 post-
vaccination to limit any effect of missing data; only 1% of 
diary cards were excluded from this analysis because of a 
lack of data.
In conclusion, PCV10 and PCV13 are highly immuno-
genic, consistent with their effectiveness, and show 
similar reactogenicity. The differences in immuno-
genicity described vary by serotype and timepoint. PCV13 
tends to produce stronger responses post-primary series 
and post-booster, while PCV10 appears to produce 
stronger responses after a single dose. PCV10 produces 
reasonable responses to non-PCV10 types 6A and 19A, 
whereas PCV13 produces only modest responses to 
serotype 3. It has been argued that a higher antibody 
concentration is required to protect against mucosal 
disease than against invasive pneumo coccal disease, but 
it is hard to assess whether or not the observed differences 
in immunogenicity would translate to differing degrees 
of protection afforded by the two vaccines. Further 
analysis of data from this trial will compare B-cell 
memory induced by PCV10 and PCV13 and will evaluate 
the effects of the two vaccines on the carriage of vaccine 
serotypes, vaccine-related serotypes, and other serotypes 
of pneumococcus, which might further elaborate the 
differences between the two vaccines.
Contributors
BT was involved in the design and day-to-day management of the trial, 
did the data analysis, and wrote the first draft of this manuscript with 
input from CDN and EKM. NTT, KB, and DYU were involved in the 
design, establishment, day-to-day management, and implementation of 
the trial. VTTD was responsible for the ELISA experiments. RAM was 
responsible for the opsonophagocytic assays. PVL and AB were involved 
in the design, and advised on and provided oversight of the immunology 
laboratory procedures. CDN advised on the statistical analyses and 
assisted with the figures. TNH was involved in the design and 
establishment, and had overall responsibility for the conduct of the trial 
in Vietnam as site principal investigator. EKM conceived the study, 
provided oversight for the conduct of the trial and data analysis, and had 
overall responsibility for all aspects of the trial as the principal 
investigator. All authors contributed to refinement of and approved the 
submitted manuscript.
Declaration of interests
All authors receive salary support from grants from the National Health 
and Medical Research Council of Australia or the Bill & Melinda Gates 
Foundation. Non-financial support (in the form of PCV10 vaccine doses) 
and funding for opsonophagocytic assays was provided by 
GlaxoSmithKline Biologicals SA. We declare no other competing 
interests.
Data sharing
The study protocol and informed consent form have been published 
previously and are freely available. Data will be made publicly available 
in accordance with the rules set out by the Bill & Melinda Gates 
Foundation.
Acknowledgments
This work was supported by the National Health and Medical Research 
Council of Australia (grant number 566792) and the Bill & Melinda 
Gates Foundation (grant number OPP1116833). GlaxoSmithKline 
Biologicals SA donated the doses of PCV10 and provided support for 
the opsonophagocytic testing. We thank the study participants and 
their families.
References
1 Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus 
pneumoniae and Haemophilus influenzae type b disease in children 
in the era of conjugate vaccines: global, regional, and national 
estimates for 2000–15. Lancet Glob Health 2018; 6: e744–57.
2 Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent 
pneumococcal conjugate vaccination on invasive pneumococcal 
disease in Finnish children—a population-based study. PLoS One 
2015; 10: e0120290.
3 Domingues CM, Verani JR, Montenegro Renoiner EI, et al. 
Effectiveness of ten-valent pneumococcal conjugate vaccine against 
invasive pneumococcal disease in Brazil: a matched case-control 
study. Lancet Respir Med 2014; 2: 464–71.
4 Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. 
Effectiveness of three pneumococcal conjugate vaccines to prevent 
invasive pneumococcal disease in Quebec, Canada. Vaccine 2015; 
33: 2684–89.
5 Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 
10-valent pneumococcal non-typeable Haemophilus influenzae 
protein D conjugate vaccine (PHiD-CV) compared to the licensed 
7vCRM vaccine. Pediatr Infect Dis J 2009; 28 (4 suppl): S66–76.
6 Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety 
of 13-valent pneumococcal conjugate vaccine in infants and 
toddlers. Pediatrics 2010; 126: e493–505.
7 Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, 
and immunologic noninferiority of a 13-valent pneumococcal 
conjugate vaccine compared to a 7-valent pneumococcal conjugate 
vaccine given with routine pediatric vaccinations in Germany. 
Vaccine 2010; 28: 4192–203.
8 Pomat WS, van den Biggelaar AHJ, Wana S, et al. Safety and 
immunogenicity of pneumococcal conjugate vaccines in a high-risk 
population: a randomised controlled trial of 10-valent and 13-valent 
PCV in Papua New Guinean infants. Clin Infect Dis 2018; published 
online Sept 3. DOI:10.1093/cid/ciy743. 
9 Prymula R, Szenborn L, Silfverdal SA, et al. Safety, reactogenicity 
and immunogenicity of two investigational pneumococcal 
protein-based vaccines: results from a randomized phase II study in 
infants. Vaccine 2017; 35: 4603–11.
10 Carmona Martinez A, Prymula R, Miranda Valdivieso M, et al. 
Immunogenicity and safety of 11- and 12-valent pneumococcal 
non-typeable Haemophilus influenzae protein D-conjugate vaccines 
(11vPHiD-CV, 12vPHiD-CV) in infants: results from a phase II, 
randomised, multicentre study. Vaccine 2019; 37: 176–86.
11 Wijmenga-Monsuur AJ, van Westen E, Knol MJ, et al. Direct 
comparison of immunogenicity induced by 10- or 13-valent 
pneumococcal conjugate vaccine around the 11-month booster in 
Dutch infants. PLoS One 2015; 10: e0144739.
12 WHO. Pneumococcal vaccines WHO position paper—2012. 
Wkly Epidemiol Rec 2012; 87: 129–44.
13 Temple B, Toan NT, Uyen DY, et al. Evaluation of different infant 
vaccination schedules incorporating pneumococcal vaccination 
(the Vietnam Pneumococcal Project): protocol of a randomised 
controlled trial. BMJ Open 2018; 8: e019795.
14 Balloch A, Licciardi PV, Leach A, Nurkka A, Tang ML. Results from 
an inter-laboratory comparison of pneumococcal serotype-specific 
IgG measurement and critical parameters that affect assay 
performance. Vaccine 2010; 28: 1333–40.
15 Balloch A, Roalfe L, Ekstrom N, et al. Interlaboratory comparison of 
Articles
www.thelancet.com/infection   Vol 19  May 2019 509
the pneumococcal multiplex opsonophagocytic assays and their 
level of agreement for determination of antibody function in 
pediatric sera. mSphere 2018; 3: e00070-18.
16 Goldblatt D, Southern J, Andrews NJ, et al. Pneumococcal conjugate 
vaccine 13 delivered as one primary and one booster dose (1 + 1) 
compared with two primary doses and a booster (2 + 1) in UK infants: 
a multicentre, parallel group randomised controlled trial. 
Lancet Infect Dis 2018; 18: 171–79.
17 Prymula R, Schuerman L. 10-valent pneumococcal nontypeable 
Haemophilus influenzae PD conjugate vaccine: Synflorix. 
Expert Rev Vaccines 2009; 8: 1479–500.
18 Nunes MC, Madhi SA. Review on the immunogenicity and safety of 
PCV-13 in infants and toddlers. Expert Rev Vaccines 2011; 10: 951–80.
19 Jódar L, Butler J, Carlone G, et al. Serological criteria for evaluation 
and licensure of new pneumococcal conjugate vaccine formulations 
for use in infants. Vaccine 2003; 21: 3265–72.
20 Voysey M, Fanshawe TR, Kelly DF, et al. Serotype-specific correlates 
of protection for pneumococcal carriage: an analysis of immunity in 
19 countries. Clin Infect Dis 2018; 66: 913–20.
21 Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific 
effectiveness and correlates of protection for the 13-valent 
pneumococcal conjugate vaccine: a postlicensure indirect cohort 
study. Lancet Infect Dis 2014; 14: 839–46.
22 Dagan R, Juergens C, Trammel J, et al. Modeling pneumococcal 
nasopharyngeal acquisition as a function of anticapsular serum 
antibody concentrations after pneumococcal conjugate vaccine 
administration. Vaccine 2016; 34: 4313–20.
23 Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic 
evaluation of serotypes causing invasive pneumococcal disease 
among children under five: the pneumococcal global serotype 
project. PLoS Med 2010; 7: e1000348.
24 Gounder PP, Bruce MG, Bruden DJ, et al. Effect of the 13-valent 
pneumococcal conjugate vaccine on nasopharyngeal colonization 
by Streptococcus pneumoniae--Alaska, 2008–2012. J Infect Dis 2014; 
209: 1251–58.
25 Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, 
Doern GV. Pneumococcal serotypes before and after introduction of 
conjugate vaccines, United States, 1999–2011(1.). Emerg Infect Dis 
2013; 19: 1074–83.
26 Oligbu G, Hsia Y, Folgori L, Collins S, Ladhani S. Pneumococcal 
conjugate vaccine failure in children: a systematic review of the 
literature. Vaccine 2016; 34: 6126–32.
27 Black S, Shinefield H, Fireman B, et al. Efficacy, safety and 
immunogenicity of heptavalent pneumococcal conjugate vaccine in 
children. Pediatr Infect Dis J 2000; 19: 187–95.
28 De Wals P, Lefebvre B, Deceuninck G, Longtin J. Incidence of 
invasive pneumococcal disease before and during an era of use of 
three different pneumococcal conjugate vaccines in Quebec. Vaccine 
2018; 36: 421–26.
29 WHO. Pneumococcal conjugate vaccines in infants and children 
under 5 years of age: WHO position paper—February 2019. 
Wkly Epidemiol Rec 2019; 94: 85–104.
30 Slotved HC, Dalby T, Harboe ZB, et al. The incidence of invasive 
pneumococcal serotype 3 disease in the Danish population is not 
reduced by PCV-13 vaccination. Heliyon 2016; 2: e00198.
31 Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal 
serotype evolution in Western Europe. BMC Infect Dis 2015; 15: 419.
32 Yu X, Gray B, Chang S, Ward JI, Edwards KM, Nahm MH. 
Immunity to cross-reactive serotypes induced by pneumococcal 
conjugate vaccines in infants. J Infect Dis 1999; 180: 1569–76.
